reports
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 6,311,250 shares at 860.020DKK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
GSK: 1 director
A director at GSK sold 6,000 shares at 1,702p and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close p...
Tarkett- Information on the total number of voting rights and shares i...
Tarkett- Information on the total number of voting rights and shares in Tarkett’s share capital as of April, 30th, 2024 PARIS, FRANCE, May, 3rd, 2024 - Information on the total number of voting rights and shares in Tarkett’s share capital as of April, 30th, 2024 (Article L233-8-II of the French Commercial Code andArticle 223-16 of the General Regulation of the Autorité des marchés financiers) DateTotal number of shares in the share capitalTotal number of voting rightsAs of April, 30th, 2024 65,550,281 Number of theoretical voting rights: 123 643 694 Number of exercisable voting rights: 123...
Tarkett- Information relative au nombre total des droits de vote et d’...
Tarkett- Information relative au nombre total des droits de vote et d’actions composant le capital social de Tarkett au 30 avril 2024 PARIS, 3 mai 2024 — Information relative au nombre total des droits de vote et d’actions composant le capital social de Tarkett au 30 avril 2024 (Articles L233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers) DateNombre d’actions composant le capital socialNombre total de droits de voteAu 30 avril 2024 65 550 281 Nombre de droits de vote théoriques : 123 643 694 Nombre de droits de vote exerçables : 123 625 135* ...
- Dominic Rose
- Naresh Chouhan
Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)
This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Small guidance raise
Q1 LCY figures beat consensus due to US rebate adjustments related to 2023 adding c5%-points to LCY growth and low SG&A cost boosting EBIT growth in Q1. Wegovy sales were below consensus but above our forecast, and we have therefore adjusted our rebate assumptions for 2024. The 2024 guidance was raised to LCY sales growth of 19–27% (18–26%) and LCY operating profit growth of 22–30% (21–29%). We reiterate our BUY and DKK1,100 target price.
Press Release: Beyfortus real-world evidence published in The Lancet s...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...
Communiqué de presse : Des données de vie réelle concernant Beyfortus ...
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...
Sanofi: 1 director
A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Tarkett: Marie Deconinck appointed member of Tarkett Supervisory Board
Tarkett: Marie Deconinck appointed member of Tarkett Supervisory Board Tarkett, a world leader in innovative and sustainable flooring and sports surface solutions, announces the appointment of Marie Deconinck as new member of the Supervisory Board, replacing her father Didier Deconinck whose departure had been anticipated and was confirmed at the Annual General Meeting on April 26, 2024. “We are delighted to welcome Marie as a new member of the Supervisory Board. As Tarkett continues its long-term plan to create sustainable value, I am confident that Marie will actively contribute to th...
Press Release: Annual General Meeting of April 30, 2024
Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2023Distribution d’un dividende en numéraire de 3,76 euros par action, dont la mise en paiement interviendra le 15 mai 2024Composition du Conseil d’administration : renouvellement de deux administrateurs et nomination de trois nouveaux administrateurs indépendants Paris, le 30 avril 2024. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2024, sous la présidence de Frédéric ...
Novartis AG: 1 director
A director at Novartis AG sold 55,000 shares at 90.477CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK1100.00) - Company consensus added
We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
Chiffre d’affaires du T1 2024: Ventes en léger retrait organique, conf...
Chiffre d’affaires du T1 2024: Ventes en léger retrait organique, conformément aux prévisions La demande de revêtements de sols en Europe et en Amérique du Nord reste faible Poursuite de la croissance du Sport dans un marché toujours solide Chiffre d’affaires du T1 2024 : Ventes en léger retrait organique, conformément aux prévisions La demande de revêtements de sols en Europe et en Amérique du Nord reste faible Poursuite de la croissance du Sport dans un marché toujours solide Résultats du premier trimestre 2024 Chiffre d’affaires en retrait organique de -2,7% par rapport au T1 ...
Q1 2024 Revenue: Organic sales slightly down, in line with forecasts, ...
Q1 2024 Revenue: Organic sales slightly down, in line with forecasts, demand for flooring in Europe and North America remains low and continued growth of Sports in a market that is still solid Q1 2024 Revenue: Organic sales slightly down, in line with forecasts Demand for flooring in Europe and North America remains low Continued growth of Sports in a market that is still solid First Quarter 2024 Results Organic decline in sales of -2.7% compared to Q1 2023, mainly due to lower volumes in Europe and North AmericaSales prices remained stable over the quart...
- Charlotte Vaisse
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Konrad Zomer
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/25/2024
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
LHN LAFARGEHOLCIM LTD.
REL RELX PLC
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
WCH WACKER CHEMIE AG
CA CARREFOUR SA
BVI BUREAU VERITAS SA
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
ORA ORANGE SA
RI PERNOD RICARD SA
ULVR UNILEVER PLC
GLE SOCIETE GENERALE S.A. CLASS A
NESN NESTLE S.A.
ENI ENI S.P.A.
BAS BASF SE
SAN SANOFI
VOW3 VOLKSWAGEN AG PREF
SY1 SYMRISE AG
01913 PRADA S.P.A.
REP REPSOL SA
MOCORP METSO OUTOTEC OYJ
KGX KION GROUP AG
MONC MONCLER SPA
ASSA B ASSA ABLOY AB CLASS B
IBE IBERDROLA SA
AZN ASTRAZENECA PLC
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
HFG HELLOFRESH SE
ADYEN ADYEN NV
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
DSY DASSAULT SYSTEMES SA
AZE AZELIS GROUP NV
ATCO A ATLAS COPCO AB
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
DSFIR KONINKLIJKE DSM N.V.
- Charlotte Vaisse
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Konrad Zomer
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/04/2024
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
LHN LAFARGEHOLCIM LTD.
REL RELX PLC
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
WCH WACKER CHEMIE AG
CA CARREFOUR SA
BVI BUREAU VERITAS SA
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
ORA ORANGE SA
RI PERNOD RICARD SA
ULVR UNILEVER PLC
GLE SOCIETE GENERALE S.A. CLASS A
NESN NESTLE S.A.
ENI ENI S.P.A.
BAS BASF SE
SAN SANOFI
VOW3 VOLKSWAGEN AG PREF
SY1 SYMRISE AG
01913 PRADA S.P.A.
REP REPSOL SA
MOCORP METSO OUTOTEC OYJ
KGX KION GROUP AG
MONC MONCLER SPA
ASSA B ASSA ABLOY AB CLASS B
IBE IBERDROLA SA
AZN ASTRAZENECA PLC
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
HFG HELLOFRESH SE
ADYEN ADYEN NV
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
DSY DASSAULT SYSTEMES SA
AZE AZELIS GROUP NV
ATCO A ATLAS COPCO AB
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
DSFIR KONINKLIJKE DSM N.V.
- Damien Choplain
- Martial Descoutures
AstraZeneca : Very reassuring Q1 supports 2024 targets
>Symbicort and Farxiga lead the way - AZN has reported much stronger than expected Q1 2024 results, mainly thanks to Farxiga and Symbicort. Revenue increased by 19% at constant exchange rates, boosted by CVRM (cardio and metabolism) and Oncology. Sales came out 7% higher than expected. Although penalised by a recent reduction in prices for Tagrisso (June 23), Imfinzi (February 24) and Faslodex in China (November 23), revenue in China increased by 13%. However, th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.